Palisade Bio Unveils Positive Phase 1a Results for Gut-Targeted Ulcerative Colitis Drug PALI-2108
I'm PortAI, I can summarize articles.
Palisade Bio Inc. has announced positive Phase 1a results for its gut-targeted ulcerative colitis drug, PALI-2108. Two abstracts will be presented at major IBD conferences in early 2026, showcasing clinical, histologic, and biomarker effects. The presentations are scheduled for January 23, 2026, at the Crohn’s & Colitis Congress in Las Vegas, and February 20, 2026, at the 21st Congress of ECCO in Stockholm. This information is generated by Public Technologies and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments